Shelley A McCormack1, Brookie M Best. 1. Pediatrics Department-Rady Children's Hospital, University of California San Diego, La Jolla, CA, USA.
Abstract
BACKGROUND: Maternal-to-fetal transfer of antiretroviral drugs contributes to prevention of vertical transmission of HIV. OBJECTIVE: This systematic review discusses published studies containing data pertaining to the pharmacokinetics of placental transfer of antiretrovirals in humans, including paired cord and maternal plasma samples collected at the time of delivery as well as ex vivo placental perfusion models. METHODS: Articles pertaining to placental transfer of antiretrovirals were identified from PubMed, from references of included articles, and from US Department of Health and Human Services Panel on Treatment of HIV-infected Pregnant Women and Prevention of Perinatal Transmission guidelines. Articles from non-human animal models or that had no original maternal-to-fetal transfer data were excluded. PRISMA guidelines were followed. RESULTS: A total of 103 published studies were identified. Data across studies appeared relatively consistent for the nucleoside reverse transcriptase inhibitors (NRTIs) and the non-nucleotide reverse transcriptase inhibitors (NNRTIs), with cord to maternal ratios approaching 1 for many of these agents. The protease inhibitors atazanavir and lopinavir exhibited consistent maternal-to-fetal transfer across studies, although the transfer may be influenced by variations in drug-binding proteins. The protease inhibitors indinavir, nelfinavir, and saquinavir exhibited unreliable placental transport, with cord blood concentrations that were frequently undetectable. Limited data, primarily from case reports, indicate that darunavir and raltegravir provide detectable placental transfer. CONCLUSION: These findings appear consistent with current guidelines of using two NRTIs plus an NNRTI, atazanavir/ritonavir, or lopinavir/ritonavir to maximize placental transfer as well as to optimally suppress maternal viral load. Darunavir/ritonavir and raltegravir may reasonably serve as second-line agents.
BACKGROUND: Maternal-to-fetal transfer of antiretroviral drugs contributes to prevention of vertical transmission of HIV. OBJECTIVE: This systematic review discusses published studies containing data pertaining to the pharmacokinetics of placental transfer of antiretrovirals in humans, including paired cord and maternal plasma samples collected at the time of delivery as well as ex vivo placental perfusion models. METHODS: Articles pertaining to placental transfer of antiretrovirals were identified from PubMed, from references of included articles, and from US Department of Health and Human Services Panel on Treatment of HIV-infected Pregnant Women and Prevention of Perinatal Transmission guidelines. Articles from non-human animal models or that had no original maternal-to-fetal transfer data were excluded. PRISMA guidelines were followed. RESULTS: A total of 103 published studies were identified. Data across studies appeared relatively consistent for the nucleoside reverse transcriptase inhibitors (NRTIs) and the non-nucleotide reverse transcriptase inhibitors (NNRTIs), with cord to maternal ratios approaching 1 for many of these agents. The protease inhibitors atazanavir and lopinavir exhibited consistent maternal-to-fetal transfer across studies, although the transfer may be influenced by variations in drug-binding proteins. The protease inhibitors indinavir, nelfinavir, and saquinavir exhibited unreliable placental transport, with cord blood concentrations that were frequently undetectable. Limited data, primarily from case reports, indicate that darunavir and raltegravir provide detectable placental transfer. CONCLUSION: These findings appear consistent with current guidelines of using two NRTIs plus an NNRTI, atazanavir/ritonavir, or lopinavir/ritonavir to maximize placental transfer as well as to optimally suppress maternal viral load. Darunavir/ritonavir and raltegravir may reasonably serve as second-line agents.
Authors: A Calcagno; L Trentini; L Marinaro; C Montrucchio; A D'Avolio; V Ghisetti; G Di Perri; S Bonora Journal: J Antimicrob Chemother Date: 2013-03-27 Impact factor: 5.790
Authors: C Vinot; L Gavard; J M Tréluyer; S Manceau; E Courbon; J M Scherrmann; X Declèves; D Duro; G Peytavin; L Mandelbrot; C Giraud Journal: Antimicrob Agents Chemother Date: 2013-01-07 Impact factor: 5.191
Authors: Angela P H Colbers; David A Hawkins; Andrea Gingelmaier; Kabamba Kabeya; Jürgen K Rockstroh; Christopher Wyen; Katharina Weizsäcker; S Tariq Sadiq; Jelena Ivanovic; Carlo Giaquinto; Graham P Taylor; José Moltó; David M Burger Journal: AIDS Date: 2013-03-13 Impact factor: 4.177
Authors: Michelle S Cespedes; Delivette Castor; Susan L Ford; Doreen Lee; Yu Lou; Gary E Pakes; Judith A Aberg Journal: J Acquir Immune Defic Syndr Date: 2013-04-15 Impact factor: 3.731
Authors: Regis Kreitchmann; Brookie M Best; Jiajia Wang; Alice Stek; Edmund Caparelli; D Heather Watts; Elizabeth Smith; David E Shapiro; Steve Rossi; Sandra K Burchett; Elizabeth Hawkins; Mark Byroads; Tim R Cressey; Mark Mirochnick Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: Tim R Cressey; Brookie M Best; Jullapong Achalapong; Alice Stek; Jiajia Wang; Nantasak Chotivanich; Prapap Yuthavisuthi; Pornnapa Suriyachai; Sinart Prommas; David E Shapiro; D Heather Watts; Elizabeth Smith; Edmund Capparelli; Regis Kreitchmann; Mark Mirochnick Journal: Br J Clin Pharmacol Date: 2013-09 Impact factor: 4.335
Authors: Adriana Weinberg; Marisa M Mussi-Pinhata; Qilu Yu; Rachel A Cohen; Volia C Almeida; Fabiana R Amaral; Laura Freimanis; Donald Robert Harris; Christiana Smith; George Siberry Journal: AIDS Res Hum Retroviruses Date: 2018-04-23 Impact factor: 2.205
Authors: Zufei Zhang; Marjorie Z Imperial; Gabriela I Patilea-Vrana; Janak Wedagedera; Lu Gaohua; Jashvant D Unadkat Journal: Drug Metab Dispos Date: 2017-06-06 Impact factor: 3.922
Authors: Bassam H Rimawi; Erica Johnson; Augustine Rajakumar; Sijia Tao; Yong Jiang; Scott Gillespie; Raymond F Schinazi; Mark Mirochnick; Martina L Badell; Rana Chakraborty Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191
Authors: Jolien J M Freriksen; Stein Schalkwijk; Angela P Colbers; Khaled Abduljalil; Frans G M Russel; David M Burger; Rick Greupink Journal: Clin Pharmacol Ther Date: 2020-01-24 Impact factor: 6.875
Authors: Jordan G Schnoll; Brian Temsamrit; Daniel Zhang; Hongjun Song; Guo-Li Ming; Kimberly M Christian Journal: J Neuroimmune Pharmacol Date: 2019-09-11 Impact factor: 4.147
Authors: Kimberly K Scarsi; Joshua P Havens; Anthony T Podany; Sean N Avedissian; Courtney V Fletcher Journal: Drugs Date: 2020-11 Impact factor: 9.546